Susquehanna International Group
EGRX

Susquehanna International Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Susquehanna International Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,087
Closed -$48.3K – 13472
2024
Q1 		$58.1K Sell
11,087
-37,509
-77% -$206K ﹤0.01% 11500
2023
Q4 		$254K Buy
48,596
+5,856
+14% +$57.8K ﹤0.01% 10181
2023
Q3 		$674K Sell
42,740
-14,266
-25% -$256K ﹤0.01% 7536
2023
Q2 		$1.11M Sell
57,006
-16,394
-22% -$389K ﹤0.01% 6441
2023
Q1 		$2.08M Buy
73,400
+54,449
+287% +$1.62M ﹤0.01% 5041
2022
Q4 		$554K Buy
18,951
+47
+0.2% +$1.5K ﹤0.01% 7593
2022
Q3 		$499K Buy
+18,904
New +$694K ﹤0.01% 8499
2022
Q2 		– Sell
-9,451
Closed -$468K – 14194
2022
Q1 		$468K Sell
9,451
-7,915
-46% -$380K ﹤0.01% 9166
2021
Q4 		$884K Buy
17,366
+7,597
+78% +$394K ﹤0.01% 7616
2021
Q3 		$545K Buy
9,769
+414
+4% +$20.4K ﹤0.01% 9154
2021
Q2 		$400K Buy
9,355
+3,398
+57% +$140K ﹤0.01% 10135
2021
Q1 		$249K Buy
+5,957
New +$277K ﹤0.01% 10996
2020
Q4 		– Sell
-6,372
Closed -$271K – 11863
2020
Q3 		$271K Buy
+6,372
New +$279K ﹤0.01% 8917
2020
Q2 		– Sell
-7,045
Closed -$351K – 11126
2020
Q1 		$324K Buy
+7,045
New +$354K ﹤0.01% 7830
2019
Q4 		– Sell
-9,317
Closed -$556K – 10848
2019
Q3 		$527K Sell
9,317
-6,586
-41% -$370K ﹤0.01% 7196
2019
Q2 		$885K Buy
15,903
+5,930
+59% +$309K ﹤0.01% 5951
2019
Q1 		$504K Sell
9,973
-11,674
-54% -$519K ﹤0.01% 6257
2018
Q4 		$872K Buy
+21,647
New +$1.12M ﹤0.01% 4948
2018
Q2 		– Sell
-3,835
Closed -$241K – 10599
2018
Q1 		$202K Sell
3,835
-17,543
-82% -$1.02M ﹤0.01% 8314
2017
Q4 		$1.14M Buy
+21,378
New +$1.19M ﹤0.01% 4964
2016
Q1 		– Sell
-33,053
Closed -$2.1M – 9811
2015
Q4 		$2.93M Buy
33,053
+1,255
+4% +$99.1K ﹤0.01% 3326
2015
Q3 		$2.35M Buy
31,798
+18,820
+145% +$1.57M ﹤0.01% 3956
2015
Q2 		$1.05M Sell
12,978
-16,764
-56% -$1.09M ﹤0.01% 6126
2015
Q1 		$1.25M Buy
+29,742
New +$844K ﹤0.01% 5314

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group's EGRX Position: Q2 2024 in Review

Susquehanna International Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 11,087 shares — an estimated $48.3K sold.

Susquehanna International Group first reported a position in EGRX in Q1 2015 and held it in 24 quarters. The position peaked at $2.93M in Q4 2015. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Susquehanna International Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 11,087 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $48.3K.
  • Susquehanna International Group first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 24 quarters.
  • Susquehanna International Group's Eagle Pharmaceuticals, Inc. position peaked at $2.93M in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.